Author:
Dimopoulos Meletios A.,Kyle Robert A.
Reference125 articles.
1. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208:1680–1685.
2. Alberts DS, Chang SY, Chen HS, Evans TL, Moon TE. Oral melphalan kinetics. Clin Pharmacol Ther 1979; 26:737–745.
3. Boccadoro M, Marmont F, Tribalto M, et al. Early responder myeloma: kinetic studies identify a patient subgroup characterized by a very poor prognosis. J Clin Oncol 1989; 7:119–125.
4. Oken MM, Harrington DP, Abramson N, et al. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma. Results of Eastern Cooperative Oncology Group study E 2479. Cancer 1997; 79:1561–1567.
5. Salmon SE, Haut A, Bonnet JD, et al. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1983; 1:453–461.